WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.074
Volume 8, Issue 2, 1684-1695. Review Article ISSN 2277– 7105

CREUTZFELDT-JAKOB DISEASE (CJD)

***S. Venkatesh and P. Joshua Arun Stanley**

India.

Article Received on
20 Dec. 2018,
Revised on 10 Jan. 2019,
Accepted on 31 Jan. 2019
DOI: 10.20959/wjpr20192-14238

***Corresponding Author**
S. Venkatesh
India.

INTRODUCTION

Creutzfeldt-Jakob Disease (CJD) exists in acquired, obtained (variation and iatrogenic), and unconstrained (sporadic) shapes. Albeit iatrogenic and variation types of CJD more often than not influence moderately youthful people, all structures may influence old people, particularly sporadic CJD. Sporadic CJD is an uncommon reason for dementia among moderately aged and old people, and commonplace cases are clinically genuinely unmistakable from increasingly regular types of neurodegenerative dementias. Be that as it may, clinical finding can be a test for the individuals who are not experienced with the illness. Luckily, certain examinations can be extremely useful. Albeit numerous instances of CJD (particularly sporadic CJD) are not thought to be obtained ailments, there is as yet a potential for ahead transmission, and certain insurances are important to ensure general wellbeing Creutzfeldt-Jakob ailment (CJD) is an ailment that has had real therapeutic, media, and political effect, in spite of its irregularity, basically as a result of its potential transmissibility with 1 type of CJD being a zoonosis. Much consideration has been focussed on variation CJD, however the most widely recognized frame is sporadic CJD, an uncommon yet essential reason for dementia among moderately aged and older people. Sporadic CJD is at present idea to be an unexpectedly happening neurodegenerative disease that isn't essentially gained by disease, yet forward transmission from influenced people may happen. Jakob first portrayed this disease in 1921; a depiction in a prior article by Creutzfeldt was reflectively and erroneously included for what we currently call CJD,[1] Logical improvements have prompted changes in the nosology of CJD throughout the years, with different illnesses of people and creatures being observed to be connected. Two of the most vital discoveries were the exhibition of the transmissibility and the focal job of the prion protein (PrP), henceforth the expression "prion illnesses".[2,3] CJD is currently isolated into 4 frames based on cause and clinico-obsessive profile. Tragically, the media (and, without a doubt, others) at times neglect to deliberately recognize

them. The neuropathological highlights of prion malady are basically neurodegenerative: neuronal misfortune, astrocytic expansion, spongiform change, and affidavit of an unusual diseaserelated type of PrP in tissues.[4,5] All prion malady are cerebrum ailments commonly including dementia; they are all around dynamic, deadly, and by and by serious.

EPIDEMOLOGY

Prion sicknesses are conceivably transmissible. Human tohuman transmission was first announced in 1974, when a55 year elderly person was depicted who created side effects of Creutzfeldt-Jakob ailment (CJD) year and a half after a corneal transplant.[6] From that point forward, transmission has been detailed after stereotactic electroencephalographic (EEG) profundity recording, human development hormone (hGH) and gonadotrophin treatment, and dura mater transplantation.[7– 10] In excess of 267 patients with iatrogenic CJD are known today and their number is developing. 6 The most critical iatrogenic reason for CJD is as yet debased cadaveric hGH. Introduction to defiled hGH happened before 1985, when recombinant development hormone wound up accessible. In an ongoing report, brooding periods in 139 patients with hGH related CJD were found to go from 5– 30 years, with a middle of 12 years.[11] One of the components impacting hatching time is genotype on polymorphic codon 129 of the prion protein quality.[12] The hatching time is altogether shorter in individuals who are homozygous for either methionine or valine on this polymorphism.[12] the second patient with hGH related CJD in the Netherlands. The patient built up the ailment 38 years after hGH infusions. As far as anyone is concerned, this is the longest brooding time frame depicted for any type of iatrogenic CJD. In numerous European and different nations, CJD is built up as, or is soon to wind up, a notifiable infection, with most nations having committed national CJD observation units. At the season of composing, 120 instances of vCJD have been diagnosed, with 114 happening in the UK.

ETIOLOGY

Creutzfeldt– Jakob sickness is the most widely recognized type of transmissible spongiform encephalopathy. This gathering of ailments, first distinguished in creatures in the seventeenth century (sheep's scrapie), is uncommon in people; its recurrence is around 1 of every a million every year, with equivalent circulation worldwide. Iatrogenic cases were watched influencing youngsters and youthful grown-ups following treatment with concentrate of development hormone.[13] A 3-year review in the UK recognized one likely and two clear instances of pediatric CJD.[14], Transmissible spongiform encephalopathies are halfway

hereditarily decided: a few transformations of the quality for PrP produce transmissible spongiform encephalopathies acquired with autosomal prevailing transmission; moreover, polymorphism of the PRP quality adjusts the clinical articulation. The illness can likewise be transmitted as an irresistible condition, and since the infection specialist has bizarre qualities it was called non-traditional transmissible operator (NCTA), at that point prion.[15] For about 15% of patients with Creutzfeldt– Jakob the infection is familial. It is transmitted in a prevailing way and a few changes of the PRP quality are known. PRP is amazingly rationed among species, especially warm blooded animals in which it was found in all species in which it was looked for. The marvel of species boundary that limits transmission starting with one animal varieties then onto the next is clarified by varieties of this quality. In people, there is a physiological polymorphism of the PRP quality that specifically impacts the outflow of the ailment, regardless of whether sporadic or transmitted iatrogenically or hereditarily. For instance, in a few families a change on codon 178 of PRP is in charge of Creutzfeldt Jakob sickness or lethal familial a sleeping disorder as per the polymorphism of codon 129. This polymorphism of codon 129 additionally assumes a job in the hatching term of iatrogenic Creutzfeldt-Jakob illness.[16] Creutzfeldt– Jakob ailment can be transmitted by uniting tainted tissue from an individual who is either sick with the sickness or in hatching. One instance of corneal graft, a dozen dura matter unions, and a couple of exploratory neurosurgical intercessions (stereo-EEG anodes recently utilized for patients with Creutzfeldt– Jakob sickness) are on record. At long last a few creators presume that blood items could decide the transmission of another variation of the sickness.[17] Another variation of Creutzfeldt– Jakob ailment influencing youthful subjects has been portrayed in the UK[18] that joins social side effects, neurological weakening, and, on neuropathological examination, amyloid plaques encompassed by spongiosis, the colorful plaques. These cases came about because of transmission of frantic bovine malady to people by means of sustenance. the most regular iatrogenic method of transmission includes the utilization of pituitary hormones (development hormone and gonadotropin). There have been more instances of Creutzfeldt–Jakob ailment in France than in whatever remains of the world after the organization of development hormone.[19] In 2009, 117 patients were known to be influenced by Creutzfeldt–Jakob malady following treatment with human development hormone extricated from dead bodies between November 1983 and July 1985. The investigation for legitimate reasons for the therapeutic documents of 100 patients who had kicked the bucket enabled the primary indications to be resolved, which in all cases included ataxia, joined with oculomotor hindrance in 54%, conduct side effects in 30%, and pyramidal signs in 30%. For a while

intellectual shortages stayed mellow or missing before the full clinical picture developed, which joined monstrous neurological disintegration with myoclonus (71% of cases), causing the patient to be disabled, and dementia in all cases. Patients kicked the bucket after a couple of months or years.

DIAGONISIS

CSF examination generally gives no incendiary suggestions. Following a while the finding of the 14-3-3 protein in the CSF is a noteworthy piece of information for diagnosis.[20] The revelation of spongiosis, neuronal exhaustion, responsive astrocytosis, and the presence of amyloid plaques with hostile to PrP immunostaining on cerebrum obsessive examination allows the conclusion of iatrogenic Creutzfeldt– Jakob disease.[21] Determination may likewise be affirmed by the western smear revelation of PrP amassing.

On X-ray, trademark checked hyperintensity (in respect to cortical dim issue flag force) of the caudate head and putamen is seen in 70– 80% of cases[22,23] however in sCJD the flag power in the thalamus remains lower than the flag in the putamen, vide infra.

Hereditary and iatrogenic CJD. Hereditary CJD is affirmed by identification of a significant PRNP transformation (on a blood test) in a suitable setting (i.e., in the clinical picture of prion malady and additionally neuropathological affirmation). The conclusion of iatrogenic CJD relies upon the ID of a significant going before system.

Sporadic CJD. The conclusion of sporadic CJD might be upheld by 3 examinations: electroencephalogram, CSF investigation, and cerebral X-ray.[24, 25] In a dominant part of cases (yet not all), the electroencephalogram demonstrates summed up, synchronous, occasional releases at somestage. In spite of the fact that not absolutely exceptional to sporadic CJD, these discoveries in an electroencephalogram are extremely suggestive in the suitable clinical setting. On the off chance that sporadic CJD isn't found at first, the electroencephalogram can be rehashed, maybe on a week by week premise.[24, 25] Estimation of the CSF 14-3-3 level is extremely useful (the National Creutzfeldt-Jakob Sickness Observation Unit [NCJDSU] gives a national CSF 14-3-3 benefit; see Reference section). A lumbar cut will as a rule be performed for suspected cases as a vital piece of barring other conceivable ailments. Since 14-3-3 is an ordinary neuronal protein that is found in lifted dimensions by and large of sporadic CJD, it must be focused on that a CSF 14-3-3 test result might be sure in an assortment of neurological conditions; the test's explicitness for sporadic

CJD is profoundly setting ward. Additionally, a negative test outcome can't totally reject sporadic CJD.[25] Cerebral imaging, ideally X-ray, is demonstrated in every speculated case to bar other conceivable ailments. Notwithstanding, in sporadic CJD, certain trademark X-ray changes might be watched, especially high flag changes in the foremost basal ganglia.[26, 27]

Variation CJD. In variation CJD, an electroencephalogram does not ordinarily demonstrate the intermittent example of sporadic CJD. The CSF 14-3-3 test isn't as touchy or as explicit all things considered in sporadic CJD.[28] The cerebral X-ray is incredibly useful; in 190% of cases, a trademark high flag change is seen in the back thalamus (the "pulvinar sign"); this isn't completely explicit, however other conceivable causes ought to be generally effectively recognized on clinical grounds. It is generally observed on T2-weighted pictures, however liquid constriction reversal recuperation (Pizazz) groupings are fundamentally increasingly delicate.[27, 29] X-ray checks have uncovered the sign at just 3 months of sickness; in the event that discoveries of an underlying sweep are negative, a recurrent output is worth thought. The inclusion of reticulo-endothelial tissue in variation CJD implies that tonsil biopsy may recognize variation CJD– related PrPSc; the strategy is generally intrusive, and negative discoveries can't totally prohibit the determination. Be that as it may, it tends to be demonstratively helpful, especially in clinically questionable or X-ray negative cases.**[24]** asymptomatic vCJD contamination was distinguished in an old patient who had experienced transfusion of one unit of non-leucodepleted red platelets from another asymptomatic contributor who consequently created vCJD.[30] The beneficiary had no signs or side effects of vCJD or some other neurological turmoil and passed on of a random ailment 5 years after the transfusion. Investigation of the codon 129 polymorphism in the PRNP quality found that this beneficiary was heterozygous (methionine/valine). No neuropathological proof of vCJD was found in the cerebrum and Western blotch for PrPSc in the mind was negative. Nonetheless, immunohistochemistry for PrPSc was sure in the spleen and a cervical lymph hub, however not in the tonsil or the reference section, and Western blotch examination affirmed the nearness of PrPSc in the spleen.[30] Albeit one test has been accounted for to have the capacity to recognize vCJD prions in the blood of non-human primates tentatively contaminated with BSE.[31]

PrP; PrP is a typical cell protein, of questionable capacity, that, in people, is encoded by the PrP quality (PRNP), which is situated on chromosome 20. In prion ailments, there are post-translational conformational changes, from the typical dominatingly a-helical structure

(PrPC) to a more b-sheeted frame (PrPSc). The exact instrument of this change is vague, and its motivation is accepted to shift with various prion infections. When the procedure starts, PrPSc keeps on causing PrPC to change over in an auto-synergist intensification. PrPSc and PrPC have diverse physico-concoction properties. Specifically, PrPSc is generally insoluble, is moderately impervious to protease debasement, will in general gather in tissues, and structures amyloid stores. PrPSc is identified with sickness pathogenesis and infectivity, however the exact connections are misty.[32,33] Following protease treatment of PrPSc, a critical center protein remains (assigned PrPRes) that is found in 2 unique sizes (type I and type II). What's more, there are diverse glycosylation examples of the ailment related protein (An and B). Accordingly, the hidden PrP found in infection can be grouped (e.g., as IIB).[34,35,36] These resultant protein types shift between various types of prion malady; in this manner, they help to recognize them.

PRNP; the pertinent quality, is essential in the sickness procedure. In hereditary structures, the job is accepted to be specifically causal, however PRNP has impacts in all types of CJD. Specifically, there is a typical polymorphism at codon 129 of the open perusing outline, whereby either methionine (M) or valine (V) might be encoded. This genotype influences powerlessness to prion sicknesses, may impact the hatching time frame in procured cases, and can even influence the clinico-neurotic phenotype of the subsequent illness.[35, 37]

TYPES

CJD is currently partitioned into 4 shapes based on cause and clinico-obsessive profile. Shockingly, the media (and, without a doubt, others) now and then neglect to deliberately recognize them. The neuropathological highlights of prion malady are basically neurodegenerative: neuronal misfortune, astrocytic expansion, spongiform change, and statement of an irregular diseaserelated type of PrP in tissues.[38, 39] All prion ailment are cerebrum diseases ordinarily including dementia; they are all around dynamic, deadly, and by and by serious.

Hereditary CJD. Hereditary CJD is related with various transformations of the PRNP quality that are right now accepted to be specifically pathogenic. The legacy is autosomal overwhelming with commonly total or high penetrance (differing to some degree from transformation to change). The clinico-neurotic infection phenotype is fairly factor, depending in any event to some degree on the specific hidden transformation.[40] Hereditary CJD is extremely uncommon, causing around 5 passings for each year in the Assembled

Kingdom. There are 2 critical actualities for the nonspecialist. Initially, hereditary CJD can clinically emulate different types of CJD, and a family ancestry of the disease might be missing.

Sporadic CJD. Sporadic CJD has an overall dissemination, with a yearly death rate of roughly 1– 2 passings for every million cases. Basically, it influences moderately aged and older people (in the Unified Kingdom, the middle age at death is 67 years [range, 20– 95 years]).[41, 42] There is a pointedly expanding frequency related with expanding age, yet with a decline in occurrence among people 170 years of age, it is dubious whether this speaks to a genuine decline in rate or an impression of underascertainment of cases among older people. The reason is obscure; the present hypothesis supports either an unconstrained change in PrP structure or a physical PRNP change that prompts an unusual type of protein. In any case, it stays conceivable that sporadic CJD is a gained ailment, and 2 case-control thinks about have detailed earlier medical procedure as a hazard factor.[43, 44] Unconstrained event would be required to deliver a proceeding with increment in the quantity of cases with expanding age, and it is surely conceivable that cases among old people are neglected, being misdiagnosed as different conditions without post-mortem examination being performed.

Iatrogenic CJD. Iatrogenic CJD is basically CJD (in all probability sporadic CJD) that is transmitted starting with one individual then onto the next by restorative or careful treatment.[46] Note that all types of prion infection are conceivably transmissible, even, amazingly, autosomal overwhelmingly acquired hereditary maladies. Also, there are expanding worries that variation CJD will prompt huge optional transmission, with 2 detailed instances of plausible blood transmission.[47, 48] Patients with cases identified with human development hormone regularly present likewise with dynamic cerebellar ataxia with just late psychological debilitation, and are generally moderately youthful, mirroring the utilization of human development hormone treatment amid adolescence.[41,45] The clinical highlights of different types of iatrogenic CJD are commonly like those of sporadic CJD.

Variation CJD. Variation CJD was first recognized in 1996, and the most punctual that beginning of side effects has been distinguished is 1994.[49] It is viewed because of ox-like spongiform encephalopathy in cows entering human sustenance, with the hazard time frame in the Unified Kingdom being commonly acknowledged as being around 1980– 1996.[50] Most cases to date have happened in the Unified Kingdom (the nation with the most noteworthy rate of ox-like spongiform encephalopathy), yet cases have been distinguished in

different nations, particularly France. The present UK information recommend a pandemic that is diminishing, with passings in the Unified Kingdom having crested in the year 2000 (with just 9 passings in 2004 and 5 out of 2005 that have been distinguished to date).[51] Notwithstanding, alert must be communicated with respect to the elucidation of these figures, not least since all patients who have been tried to date (139 of 159 patients in the Assembled Kingdom) have had PRNP-129 MM, and there are great hypothetical purposes behind trusting that other 129 genotypes will be influenced and that they will have a more extended hatching period.

CONCLUSION

CJD is an extremely uncommon sickness that might be gained by disease and optionally transmitted. The most well-known shape (sporadic CJD) influences just roughly 1– 2 individuals for every million every year, a large portion of whom are moderately aged or old, with conceivable underascertainment of cases among individuals with more established age. The ailment profile is typically a striking one, yet most clinicians won't have had much (assuming any) past involvement with cases, and there is no basic, noninvasive indicative test for living patients. Be that as it may, the clinical highlights and certain examinations ought to permit a sensibly sure clinical analysis in many cases, and there are national reconnaissance and research units in the Unified Kingdom and numerous different nations that can give exhortation and help.Treatment of prion infections is just symptomatic. It is troublesome since the course is quick, and it is both iatrogenic and irresistible. The therapeutic group and the family should be reminded that the malady can be transmitted by vaccination of tainted tissue, and that cleanliness alerts should be watched (wearing gloves for blood examining; confining surgeries to the barest least). Specific consideration ought to be taken with patients who have been given development hormone removed from the pituitary organ, have experienced blood transfusion, and to a specific degree the individuals who lived in the UK amid the spongiform ox-like encephalopathy pandemics (1980– 1996) since they are hypothetically a conceivable store for the illness. They should deliberately be barred from blood and organ gift. For the individuals who need to experience medical procedure, especially neurosurgery, explicit methods are required for sterilization of the hardware. Conversely, there is no proof that close contact with tainted patients puts people in danger, and there is no known transmission to posterity (fetal transmission). Another ramifications of our contemplate is that CJD can grow even after a low portion of hGH. This case afresh affirms that overall close checking of any type of iatrogenic CJD is obligatory.

REFERENCES

1. Katscher F. It's Jakob's disease, not Creutzfeldt's. Nature, 1998; 393: 11.
2. Prusiner SB. An introduction to prion biology and diseases. In: Prusiner SB, ed. Prion biology and Diseases. New York: Cold Spring Harbour Laboratory Press, 2004; 1–87.
3. Prusiner SB. Development of the prion concept. In: Prusiner SB, ed. Prion biology and diseases. New York: Cold Spring Harbour Laboratory Press, 2004; 89–141.P.
4. Ironside JW. General features of prion diseases. In: Clark CM, Trojanowski JQ, eds. Neurodegenerative diseases. USA: McGraw-Hill, 2000; 329–40.
5. DeArmond SJ, Ironside JW, Bouzamondo-Bernstein E, Peretz D, Fraser JR. Neuropathology of prion diseases. In: Prusiner SB, ed. Prion biology and diseases. New York: Cold Spring Harbour Laboratory Press, 2004; 777–856.
6. Duffy P, Wolf J, Collins G, et al. Possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med, 1974; 290: 692–3.
7. Bernoulli C, Siegfried J, Baumgartner G, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet, 1977; i: 478–9.
8. Koch TK, Berg BO, De Armond SJ, et al. Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism: possible relation to the administration of cadaveric human growth hormone. N Engl J Med, 1985; 313: 731–3.
9. Cochius JI, Burns RJ, Blumbergs PC, et al. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. Aust NZ J Med, 1990; 20: 592–3.
10. Thadani V, Penar PL, Partington J, et al. Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft: case report. J Neurosurg, 1988; 69: 766–9.
11. Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology, 2000; 55: 1075–81.
12. Huillard d'Aignaux J, Costagliola D, Maccario J, et al. Incubation period of Creutzfeldt Jakob disease in human growth hormone recipients in France. Neurology, 1999; 53: 1197–201.
13. Hintz R, McGilivray M, Joy A et al. (1985). Fatal degenerative Neurologic disease in patients who received pituitaryderived growth hormone. MMWR Morbid Mortal Weekly Rep 34: 359–360, 365–366.
14. Verity CM, Nicoll A, Will RG et al. (2000). Variant Creutzfeldt–Jakob disease in UK children: a national surveillance study. Lancet, 356: 1224–1227.
15. Prusiner SB (1982). Novel proteinaceous particles cause scrapie. Science, 216: 136–144.
16. Hsiao K, Prusiner SB (1990). Inherited human prion diseases. Neurology, 40: 1820–1827.

17. Editorial team (2007). Fourth case of transfusion-associated vCJD infection in the United Kingdom. Euro Surveill 12: pii =3117. Available online at http: //www.eurosurveillance.org/ViewArticle.aspx?ArticleId =3117.
18. Will RG, Ironside JW, Zeidler M et al. (1996). A new variant of Creutzfeldt–Jakob disease in the UK. Lancet, 374: 921–925.
19. Billette de Villemeur T, Gourmelen M, Beauvais P et al. (1992). Maladie de Creutzfeldt-Jakob chez quatre enfants traite´s par hormone de croissance. Rev Neurol (Paris), 148: 328–334.
20. Beaudry P, Cohen P, Brandel JP et al. (1999). 14-3-3 Protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. Dement Geriatr Cogn Disord, 10: 40–46.
21. Billette de Villemeur T, Deslys JP, Dormont D et al. (1994). Iatrogenic Creutzfeldt–Jakob disease in three growth hormone recipients: pathological findings. Neuropathol Appl Neurobiol, 20: 111–117.
22. Finkenstaedt M, Szudra A, Zerr I *et al.* (1996) MR imaging of Creutzfeldt-Jakob disease. *Radiology*, 199: 793–8.
23. Schroter A, Zerr I, Henkel K *et al.* (2000) Magnetic Resonance Imaging in the Clinical Diagnosis of Creutzfeldt-Jakob Disease. *Archives of Neurology*, 57: 1751–7.
24. Knight R, Brazier M, Collins SJ. Human prion diseases: cause, clinical and diagnostic aspects. In: Rabenau HF, Cinatl J, Doerr HW, eds. Prions: a challenge for science, medicine and the public health system. Basel, Switzerland: Karger, 2004; 72–97.
25. Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3- 3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology, 2000; 55: 811–5.
26. Finkenstaedt M, Szudra A, Zerr I, et al. MR imaging of CreutzfeldtJakob disease. Radiology, 1996; 199: 793–8.
27. Collie DA, Sellar RJ, Zeidler M, Colchester AFC, Knight R, Will RG. MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. Clinical Radiology, 2001; 56: 726–39.
28. Green AJE, Thompson EJ, Stewart GE, et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt Jakob disease. J Neurol Neurosurg Psychiatry, 2001; 70: 744–8.
29. Collie DA, Summers DM, Sellar RJ, et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. Am J Neuroradiol, 2003; 24: 1560–9. Downloaded fromhttp: //cid.o

30. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet, 2004; 364: 527-9.\
31. Amorfix detects vCJD prions in blood from non-human primates; http: //www.analytica-world.com/news/e/108609/
32. Prusiner SB. Development of the prion concept. In: Prusiner SB, ed. Prion biology and diseases. New York: Cold Spring Harbour Laboratory Press, 2004; 89–141.P.
33. Prusiner SB, Scott MR, DeArmond SJ, Carlson G. Transmission and replication of prions. In: Prusiner SB, ed. Prion biology and diseases. New York: Cold Spring Harbour Laboratory Press, 2004; 187–242.
34. Head MW, Bunn TJR, Bishop MT, et al. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991–2002. Ann Neurol, 2004; 55: 851–9.
35. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol, 1999; 46: 224–33.
36. Polymenidou M, Stoeck K, Glatzel M, Vey M, Bellon A, Aguzzi A. Coexistence of multiple PrPSc types in individuals with Creutzfeldt Jakob disease. Lancet, 2005; 4: 795.
37. Windl O, Dempster M, Estibeiro, et al. Genetic basis of Creutzfeldt Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. Hum Genet, 1996; 98: 259–64.
38. Ironside JW. General features of prion diseases. In: Clark CM, Trojanowski JQ, eds. Neurodegenerative diseases. USA: McGraw-Hill, 2000; 329–40.
39. DeArmond SJ, Ironside JW, Bouzamondo-Bernstein E, Peretz D, Fraser JR. Neuropathology of prion diseases. In: Prusiner SB, ed. Prion biology and diseases. New York: Cold Spring Harbour Laboratory Press, 2004; 777–856.
40. Kovacs GG, Trabattoni G, Hainfellner JA, Ironside JW, Knight RSG, Budka H. Mutations of the prion protein gene: phenotypic spectrum. J Neurol, 2002; 249: 1567–82.
41. Will RG, Alpers MP, Dormont D, Schonberger LB. Infectious and sporadic prion diseases. In: Prusiner SB, ed. Prion biology and diseases. New York: Cold Spring Harbor Laboratory Press, 2004; 629–71.
42. The 13th National Creutzfeldt-Jakob Disease Surveillance Unit annual report, 2004.
43. Ward HJT, Everington D, Croes EA, et al. Sporadic Creutzfeldt-Jakob disease and surgery: A case-control study using community controls. Neurology, 2002; 59: 543–8.

44. Collins S, Law MG, Fletcher A, Boyd A, Kaldor J, Masters CL. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet, 1999; 353: 693–7.
45. Knight R, Brazier M, Collins SJ. Human prion diseases: cause, clinical and diagnostic aspects. In: Rabenau HF, Cinatl J, Doerr HW, eds. Prions: a challenge for science, medicine and the public health system. Basel, Switzerland: Karger, 2004; 72–97.
46. Brown P, Preece M, Brandel J-P, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology, 2000; 55: 1075–81.
47. Llewelyn CA, Hewitt PA, Knight RSG, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet, 2004; 363: 417–21.
48. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet, 2004; 364: 527–9.
49. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt Jakob disease in the UK. Lancet, 1996; 347: 921–5.
50. Knight R. The relationship between new variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Vox Sang, 1999; 76: 203–8.
51. The National Creutzfeldt-Jakob Disease Surveillance Unit annual report, 2005.